TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9357934
Drug: Water and
Normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Rose Water and Ivy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water and half-strength formula as slow infusion
Study: 9357934
Drug: Full-strength formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength formula as slow infusion
Study: 1605959
Drug: Steroids +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids + acyclovir (intravenous doses for Ramsay Hunt's syndrome)
Study: 1605959
Drug: Steroids (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (control group for Bell's palsy)
Study: 1605959
Drug: Acyclovir (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (oral doses for Bell's palsy)
Study: 8773063
Drug: Paracetamol 10
Normalized name: Paracetamol 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 10 mg/kg
Study: 4072592
Drug: Aminophenazone 4
Normalized name: Aminophenazon
DrugBank: Aminophenazone (DB01424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophenazone 4 mg/kg and Diazepam 0.2 mg/kg
Study: 29359279
Drug: High-dose baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose baclofen
Study: 22705951
Drug: Ultrasound-guided ilioinguinal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided ilioinguinal and iliohypogastric nerve block with 20 mL bupivacaine 0.5%
Study: 22705951
Drug: Placebo block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo block with 20 mL saline
Study: 8403274
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) (6 mg/kg)
Study: 12011121
Drug: Aza C
Normalized name: BAZA CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza C (75 mg/m² subcutaneous for 7 days every 4 weeks)
Study: 10745332
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IVIG) 1 g/kg on three consecutive days
Study: 7874928
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) - 400 micrograms of albuterol
Study: 7874928
Drug: Rotahaler -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotahaler - 400 micrograms of albuterol
Study: 7874928
Drug: Diskhaler -
Normalized name: zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Diskhaler - 400 micrograms of albuterol
Study: 2211570
Drug: Buspirone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (mean dose 41-54 mg/day from Week 2 to end of study)
Study: 30831541
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin (2 capsules of 5 mg each) once a day 1 hour before bedtime for 12 weeks
Study: 27864672
Drug: Rhinolight® intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinolight® intranasal phototherapy (combination of UV‐B, UV‐A, and high‐intensity visible light)
Study: 27864672
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (low‐intensity visible white light intranasal phototherapy)
Study: 27864672
Drug: Rhinolight® intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinolight® intranasal phototherapy
Study: 23083020
Drug: Quetiapine 400
Normalized name: quetiapine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 400 mg/day
Study: 20881844
Drug: Quetiapine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 800 mg/day
Study: 19930006
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg/metformin
Study: 19930006
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg/metformin
Study: 19930006
Drug: liraglutide (monotherapy)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide (monotherapy)
Study: 19930006
Drug: glimepiride/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride/metformin
Study: 16426800
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly functional-skills training
Study: 16426800
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of resistance and functional-skills training
Study: 12044130
Drug: Alternative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative medicine therapies (specifics not provided)
Study: 12044130
Drug: Placebo effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo effect of unconventional medicine
Study: 24311403
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy
Study: 7892882
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium augmentation
Study: 2576217
Drug: Vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.2 mg/kg
Study: 2576217
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg/kg
Study: 2576217
Drug: Vecuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.4 mg/kg
Study: 795434
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate (Nerisona) in cream, ointment, and fatty ointment
Study: 795434
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate (Nerisona) ointment
Study: 795434
Drug: Commercial preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial preparations (beta‐methasone‐17‐valerate, fluocinonide, fluocinolone acetonide, flumetasone pivalate, desoximetasone)
Study: 23549824
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 4 ng/mL (group R4)
Study: 23549824
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 2 ng/mL (group R2)
Study: 23549824
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect-site concentration of 6 ng/mL (group R6)
Study: 19414206
Drug: 5.6 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 mmol/l cutoff for impaired fasting glucose
Study: 19414206
Drug: 6.1 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.1 mmol/l cutoff for impaired fasting glucose
Study: 16673249
Drug: Neoadjuvant TAC
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant TAC chemotherapy
Study: 15220788
Drug: 12 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/h ropivacaine, 0.1% (group R)
Study: 15220788
Drug: 12 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/h saline (group N)
Study: 12941031
Drug: Oral heparin/SNAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral heparin/SNAC (90 000 U heparin)
Study: 12941031
Drug: Oral heparin/SNAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral heparin/SNAC (60 000 U heparin)
Study: 12941031
Drug: Subcutaneous UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous UFH (5000 U)
Study: 10438403
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor (GRF) 500 microg twice daily
Study: 7760609
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with busulphan or hydroxyurea (no IFN-alpha)
Study: 2138703
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion (0.3 micrograms/min)
Study: 6985706
Drug: Sulfinpyrazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (200 mg four times a day)
Study: 26288467
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g single supervised dose of azithromycin
Study: 26288467
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin once daily for 5 days (conventional dose)
Study: 16979581
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive therapy (CT)
Study: 16979581
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive therapy (CT) and Psychoeducational support groups
Study: 8182401
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and placebo tablets
Study: 3885203
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg daily
Study: 27529693
Drug: Play-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play-based intervention (six clinic play-sessions, weekly home-modules, one-month home follow-up)
Study: 24431325
Drug: Calcium-sensing receptor-activating
Normalized name: activated charcoal / calcium carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-sensing receptor-activating amino acids (CaSR-AAAs) L-tryptophan, L-phenylalanine, and L-histidine
Study: 24431325
Drug: Dibasic amino
Normalized name: Dibasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibasic amino acids (DAAs) L-arginine and L-lysine
Study: 24431325
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (methylcellulose capsules)
Study: 22622073
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (surgical exclusion of the internal carotid artery stump combined with endarterectomy of the external carotid artery)
Study: 29950826
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/9.6 µg
Study: 29950826
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/7.2 µg
Study: 29950826
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 9/9.6 µg
Study: 29950826
Drug: Glycopyrrolate (GP)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (GP) MDI 36 µg
Study: 29950826
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (FF) MDI 9.6 µg
Study: 26248047
Drug: Quinidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (600 mg PO)
Study: 26248047
Drug: Naloxegol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol (25 mg PO)
Study: 26248047
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg/70 kg IV)
Study: 26248047
Drug: Quinidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine and naloxegol combination
Study: 19606937
Drug: Amlodipine/valsartan combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan combination therapy
Study: 17626056
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily)
Study: 17626056
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy
Study: 16307967
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg oral misoprostol (single-dose)
Study: 16307967
Drug: 1200 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 microg oral misoprostol (repeated-dose)
Study: 9795070
Drug: New levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New levodopa/benserazide dual-release formulation (DRF)
Study: 9795070
Drug: Conventional slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional slow-release formulation (SRF)
Study: 25915168
Drug: Aprepitant (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (375 mg once daily for 2 weeks)
Study: 21407132
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (NaNO(3) 10 mg·kg(‐1) of body mass)
Study: 19585385
Drug: Intraprostatic injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injections with mepivacaine epinephrine
Study: 19585385
Drug: No intraprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraprostatic injections
Study: 17760598
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or 1:1 eutectic mixture of local anesthetics (EMLA) cream
Study: 15220241
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 to 45 mg, titrated based on tolerability)
Study: 9702847
Drug: Sustained-release tablet
Normalized name: Oratuss 12 Sustained-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablet of naproxen (500 mg once daily)
Study: 9702847
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet of naproxen (250 mg twice daily)
Study: 2478790
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg UD-CG 115 BS (pimobendan)
Study: 2478790
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg UD-CG 115 BS (pimobendan)
Study: 335788
Drug: Pizotifen (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (4-10 mg daily)
Study: 18624588
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) - Individual format (CBT-I)
Study: 18624588
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) - Group format (CBT-G)
Study: 18624588
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy (IPT) - Group format (IPT-G)
Study: 12665638
Drug: Extended letter
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended letter outlining treatment strategies based on subsequent central DXA scan results
Study: 10560596
Drug: Celecoxib 50
Normalized name: celecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 50 mg twice a day
Study: 1879032
Drug: Therapeutic group
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic group (eleutherosides treatment)
Study: 1879032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (insulin and potassium chloride treatment)
Study: 6461243
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of ferrous sulphate
Study: 6461243
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of ferrous sulphate
Study: 6461243
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of ferrous sulphate
Study: 31100545
Drug: Callisthenic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Callisthenic training program (MG)
Study: 26603110
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of remifentanil (REM) at 0.05 μg/kg/min
Study: 26603110
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of remifentanil (REM)
Study: 22994060
Drug: Mesotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesotherapy with 2% procaine solution
Study: 22994060
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% physiological solution)
Study: 20200964
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of cholecalciferol and 1000 mg of calcium (calcium carbonate)
Study: 18005834
Drug: Midpalatal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midpalatal implant
Study: 16223887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of models I and II
Study: 12297390
Drug: TA-CIN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-CIN vaccine (533 micro g dose)
Study: 12297390
Drug: TA-CIN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-CIN vaccine (26, 128, 533 micro g doses)
Study: 25200570
Drug: Dapagliflozin 2.5
Normalized name: dapagliflozin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 2.5 mg twice daily
Study: 20302683
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride nasal spray, 0.6% (OLO) + Fluticasone nasal spray, 50 micrograms (FNS)
Study: 20302683
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 0.1% (AZE) + Fluticasone nasal spray, 50 micrograms (FNS)
Study: 15602116
Drug: Sertraline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline with cognitive behavioural therapy
Study: 10537240
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and self-care education added to pharmaceutical treatment
Study: 2112882
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human alpha-interferon (4 million units per day, three times weekly for 16 weeks)
Study: 369300
Drug: Lithium medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium medication (24 mval/day to 36 mval/day)
Study: 30428772
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual (TaU)
Study: 18413111
Drug: SADBE sensitization
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: SADBE sensitization doses (12.5, 25, 50, or 250 microg)
Study: 18413111
Drug: Elicitation doses
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elicitation doses (0, 0.2, 2, 20, and 200 microg)
Study: 14725822
Drug: Trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 100 mg
Study: 10220927
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 or 0.8 g/kg)
Study: 760861
Drug: Daily chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chemotherapy with reinforcements every 3 months
Study: 760861
Drug: Reinforcement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement therapy only every 6 weeks
Study: 22214885
Drug: Actions enabling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actions enabling benefit from misfortune (e.g., betting on stock decline)
Study: 16126118
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and 120 mg diltiazem
Study: 11791949
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (Bupropion SR and Methylphenidate)
Study: 10408666
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (400 mg/day) for 60 days
Study: 10408666
Drug: Zinc plus
Normalized name: Zinc plus Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc plus arginine supplementation (4 g/day) for 60 days
Study: 10408666
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vaccine only)
Study: 31439007
Drug: Sensor-equipped insoles
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sensor-equipped insoles combined with photo documentation and smartphone application (Smart Prevent Diabetic Feet Application) for daily foot temperature measurements.
Study: 27937077
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (RJ) - 9 capsules (350 mg/capsule) per day for 3 months
Study: 27937077
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 9 capsules per day for 3 months
Study: 25275693
Drug: Vaginal insert
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal insert containing 10 mg timed-release dinoprostone (PGE2)
Study: 19497091
Drug: Acetylcysteine 1200
Normalized name: acetylcysteine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 1200 mg orally twice daily for two doses before and two doses after the procedure
Study: 15983801
Drug: 100 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ng/ml ketamine
Study: 15151264
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol pulse doses (2‐8 mcg/3x/week)